Sugi Predict

Sugi Predict / Targets / PARP10

PARP10

Protein mono-ADP-ribosyltransferase PARP10 · Q53GL7 · PARP10 on Sugi Atlas →

87,182 patent compounds predicted against PARP10, 52,821 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Tricyclazole Tricyclazole (SCHEMBL23082) 0.66 14/20
SCHEMBL77571 SCHEMBL77571 0.70 13/20
SCHEMBL67710 SCHEMBL67710 1.00 12/20
SCHEMBL119689 SCHEMBL119689 1.00 11/20
Terephthalamide Terephthalamide (SCHEMBL197479) 0.59 11/20
SCHEMBL123731 SCHEMBL123731 1.00 10/20
Terephthalamide Terephthalamide (SCHEMBL23774) 0.68 10/20
SCHEMBL61340 SCHEMBL61340 0.53 9/20
SCHEMBL186305 SCHEMBL186305 0.53 8/20
SCHEMBL201761 SCHEMBL201761 1.00 7/20
SCHEMBL201939 SCHEMBL201939 0.67 7/20
SCHEMBL189795 SCHEMBL189795 0.50 7/20
SCHEMBL195348 SCHEMBL195348 0.50 7/20
SCHEMBL56532 SCHEMBL56532 0.74 6/20
SCHEMBL149199 SCHEMBL149199 0.68 6/20
SCHEMBL72082 SCHEMBL72082 0.59 6/20
SCHEMBL81903 SCHEMBL81903 0.58 6/20
SCHEMBL154421 SCHEMBL154421 0.57 6/20
SCHEMBL190288 SCHEMBL190288 0.56 6/20
SCHEMBL84429 SCHEMBL84429 0.55 6/20

Clinical trials — most relevant to PARP10 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors PHASE1/PHASE2RECRUITING
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) PHASE2RECRUITING
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies PHASE1/PHASE2RECRUITING
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA) PHASE1/PHASE2COMPLETED
Olaparib In Metastatic Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer PHASE2COMPLETED
An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors PHASE1/PHASE2RECRUITING
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib PHASE2COMPLETED
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer PHASE2ACTIVE_NOT_RECRUITING
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial PHASE2RECRUITING
Phase II ABT-888 With Cyclophosphamide PHASE2COMPLETED
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer PHASE1COMPLETED
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults PHASE1RECRUITING
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer PHASE1UNKNOWN
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers PHASE1COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors PHASE1COMPLETED
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer PHASE1ACTIVE_NOT_RECRUITING
Pre-Operative Radiation and Veliparib for Breast Cancer PHASE1COMPLETED
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts PHASE1ACTIVE_NOT_RECRUITING
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma PHASE1ACTIVE_NOT_RECRUITING
PET Imaging of PARP Activity in Cancer EARLY_PHASE1UNKNOWN
Sirtuin1 in COVID19 Patients nanUNKNOWN
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer nanNO_LONGER_AVAILABLE
Role of Genetic Factors in the Development of Lung Disease nanRECRUITING
Project SIRT6 Activator nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a PARP10 binder may also engage these)

ProteinNameSimilarity
Q8CIE4 — 0.995 Q8CIE4 →
P27106 — 0.985 P27106 →
A8VU90 — 0.984 A8VU90 →
A7E3N7 — 0.984 A7E3N7 →
Q66H85 — 0.984 Q66H85 →
A1L3T7 — 0.984 A1L3T7 →
Q14296 — 0.983 Q14296 →
Q400G9 — 0.983 Q400G9 →
Q8BTN6 — 0.983 Q8BTN6 →
Q8TER5 — 0.981 Q8TER5 →
Q9H8Y5 — 0.980 Q9H8Y5 →
Q2LGB3 — 0.980 Q2LGB3 →
Q3UYR4 — 0.980 Q3UYR4 →
Q9CW07 — 0.980 Q9CW07 →
Q17RC7 — 0.979 Q17RC7 →
Q8K330 — 0.979 Q8K330 →
Q9H6E5 — 0.979 Q9H6E5 →
O94761 — 0.979 O94761 →
Q96MK2 — 0.979 Q96MK2 →
Q96PD5 — 0.979 Q96PD5 →
Q1JPD6 — 0.979 Q1JPD6 →
Q96B70 — 0.979 Q96B70 →
Q7Z3H0 — 0.979 Q7Z3H0 →
A2A3L6 — 0.979 A2A3L6 →
Q3SWY4 — 0.978 Q3SWY4 →
D2HS90 — 0.978 D2HS90 →
Q17RM4 — 0.978 Q17RM4 →
Q16671 — 0.977 Q16671 →
A0A8I3PMN2 — 0.977 A0A8I3PMN2 →
Q921Q7 — 0.977 Q921Q7 →